Korea’s Biotech Moment and the Capital Reforms to Supercharge It

The global biopharma innovation map is being redrawn, and South Korea has emerged as one of its most consequential new hubs. Strong science, world-class clinical infrastructure, and a maturing capital ecosystem have positioned Korea as a source of first-in-class and best-in-class innovation. Yet structural capital dynamics systematically prevent Korea from capturing the full value of what it creates. Discover the reforms and mechanisms that can elevate Korea beyond regional innovation incubator to true global biopharma leader in our latest white paper.

Download Whitepaper: Korea’s Biotech Moment and the Capital Reforms to Supercharge It